Self-Assessment Post-Test
SELF-ASSESSMENT POST-TEST There are no fees for participating and receiving CME credit for this activity. During the period May 2005 through May 31, 2006, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to the Postgraduate Institute for Medicine. The Evolving Role of -Blockers in Benign Prostatic Hyperplasia and Beyond 1. 2. 3. 4. 5. 6. 7. 8. In the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study, which of the following statements reflects the study findings? a. At 52 weeks, the terazosin and combination groups had significantly lower symptom scores than the placebo and finasteride groups. b. Prostate volume reduction and a decrease in prostatespecific antigen (PSA) level were noted in patients in the finasteride and combination arms of the study. c. both a and b In the Prospective European Doxazosin and Combination Therapy (PREDICT) Trial, the 2 study arms with the most favorable results in terms of International Prostate Symptom Score, maximum flow rate, quality-of-life score, and benign prostatic hyperplasia (BPH) Impact Index score were ______. a. the -adrenergic receptor blocker and the combination (-adrenergic receptor blocker and 5--reductase inhibitor) arms b. the 5--reductase inhibitor and the combination (-adrenergic receptor blocker and 5--reductase inhibitor) arms In the Medical Therapy of Prostatic Symptoms (MTOPS) Trial, overall risk of clinical progression of BPH was significantly reduced by which treatment? a. finasteride b. doxazosin c. combination finasteride/doxazosin d. all of the above In evaluating the effect of treatment on acute urinary retention in the MTOPS Trial, which drug reduced the cumulative incidence of crossover to invasive therapy? a. finasteride b. doxazosin The incidence of some degree of erectile dysfunction (ED) in men over the age of 40 is estimated at ______. a. 23% b. 37% c. 42% d. 50% or higher According to the Cologne Male Survey by Braun and colleagues, the overall prevalence of ED correlated with age and which of the following comorbidities? a. hypertension b. diabetes c. pelvic surgery d. lower urinary tract symptoms e. all of the above It has been shown in controlled studies that ______ antagonists can selectively decrease tone in the bladder neck and prostate, whereas ______ antagonists are thought to be responsible for unpleasant side effects, such as postural hypotension and dizziness. a. 1-; 2b. 2-; 1Which of the following drugs is least likely to be discontinued because of patient dizziness? a. alfuzosin b. doxazosin c. tamsulosin d. terazosin 9. The US Food and Drug Administration has approved percent free PSA (% fPSA) as a marker to help differentiate men with BPH from those with prostate cancer. a. true b. false 10. fPSA is composed of multiple distinct molecular forms of PSA that can originate from ______. a. cancer b. benign peripheral tissue c. transition zone tissue d. all of the above 11. Which of the following does not describe a symptom of category II chronic bacterial prostatitis? a. recurrent lower urinary tract infections b. discomfort of more than 3 months duration c. chronic infection of the prostate gland d. a positive urine culture 12. Category IV prostatitis is diagnosed by the observation of excessive leukocytosis in specimens of expressed prostatic urine or semen. a. true b. false 13. According to Dr. Nickel, which of the following is true? The risk of prostatitis recurrence is reduced most effectively through treatment with ______. a. long-term therapy with the fluoroquinolone class of antibiotics b. combination -blocker therapy and antibiotic treatment 14. -Blocker therapy appears to reduce voiding symptoms and risk of acute urinary retention after transurethral microwave thermal therapy. a. true b. false 15. The presenting symptoms of primary bladder neck obstruction are ______ in men and women. a. the same b. different 16. Chronic urinary retention is often associated with which of the following factors? a. urinary tract infection b. chronic renal insufficiency c. diabetes d. neurologic disorders e. all of the above 17. Which of the following signals a risk of acute urinary retention in patients subsequent to administration of cholinergic antagonists or -adrenergic agonists? a. lower urinary tract symptoms b. age over 40 years c. presence of bladder outlet obstruction d. recent transurethral ultrasound-guided biopsy 18. Methods to avoid acute urinary retention following outpatient inguinal herniorrhaphy include ______. a. limiting perioperative fluid volume b. effective pain management c. administration of a preoperative -adrenergic agonist d. all of the above EVALUATION FORM The Evolving Role of -Blockers in Benign Prostatic Hyperplasia and Beyond Project ID: 1589 ES 13 Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgement of participation for this activity. VOL. 7 SUPPL. 8 2005 REVIEWS IN UROLOGY S57 Please answer the following questions by circling the appropriate rating: 5 Outstanding 4 Good 3 Satisfactory 2 Fair 1 Poor EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES Upon completion of this activity, participants should be better able to: • Discuss the role of -blockers in the treatment of benign prostatic hyperplasia. • Discuss the evidence for treating and preventing acute urinary retention with -blockers. • Discuss the treatment of lower urinary tract symptoms, including bladder neck hypertrophy. • Identify the role of benign prostate-specific antigen as a potential marker for benign prostatic hyperplasia. • Describe how combination therapy can be used to prevent progression of benign prostatic hyperplasia. 5 5 5 5 5 4 4 4 4 4 3 3 3 3 3 2 2 2 2 2 1 1 1 1 1 5 5 5 5 4 4 4 4 3 3 3 3 2 2 2 2 1 1 1 1 OVERALL EFFECTIVENESS OF THE ACTIVITY • • • • Was timely and will influence how I practice Will assist me in improving patient care Fulfilled my educational needs Avoided commercial bias or influence IMPACT OF THE ACTIVITY The information presented: (check all that apply) ❒ Reinforced my current practice/treatment habits. ❒ Provided new ideas or information I expect to use. ❒ Will improve my practice/patient outcomes. ❒ Enhanced my current knowledge base. ❒ Yes Will the information presented cause you to make any changes in your practice? ❒ No If yes, please describe any change(s) you plan to make in your practice as a result of this activity: How committed are you to making these changes? (Very committed) 5 4 3 2 1 (Not at all committed) FUTURE ACTIVITIES Do you feel future activities on this subject matter are necessary and/or important to your practice? ❒ Yes ❒ No Please list any other topics that would be of interest to you for future educational activities: FOLLOW-UP As part of our ongoing continuous quality-improvement effort, we conduct post-activity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey: ❒ Yes, I would be interested in participating in a follow-up survey. ❒ No, I’m not interested in participating in a follow-up survey. Additional comments about this activity: POST-TEST ANSWER KEY 1___ 2___ 3___ 4___ 5___ 6___ 7___ 8___ 9___ 10___ 11___ 12___ 13___ 14___ 15___ 16___ 17___ 18___ Request for Credit Name Organization Address City, State, Zip Telephone E-Mail Degree Specialty Fax I certify my actual time spent to complete this educational activity to be: ❒ I participated in the entire activity and claim 2.5 credits. ❒ I participated in only part of the activity and claim ______ credits. Signature S58 VOL. 7 SUPPL. 8 2005 If you wish to receive acknowledgement of participation for this activity, please complete the post-test by selecting the best answer to each question, complete this evaluation verification of participation, and FAX to: 303-790-4876. Date Completed REVIEWS IN UROLOGY